---
title: "IDEAYA starts Phase 1 trial for IDE034, promising B7H3/PTK7 bispecific drug. Targets solid tumors. 30-40% express B7H3/PTK7."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276876823.md"
description: "A clinical trial is being conducted to evaluate the safety, tolerance, and pharmacokinetics (PK) of IDE034 in Phase 1 dose escalation. IDE034 is being tested both as a standalone treatment and in conjunction with the company's exclusive PARG inhibitor, IDE161. The target population includes patients with various solid tumor types, with B7H3/PTK7 expression observed in 30-40% of cases. Tumor types under investigation include lung, breast, ovarian, and colorectal cancer."
datetime: "2026-02-25T11:01:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276876823.md)
  - [en](https://longbridge.com/en/news/276876823.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276876823.md)
---

# IDEAYA starts Phase 1 trial for IDE034, promising B7H3/PTK7 bispecific drug. Targets solid tumors. 30-40% express B7H3/PTK7.

A clinical trial is being conducted to evaluate the safety, tolerance, and pharmacokinetics (PK) of IDE034 in Phase 1 dose escalation. IDE034 is being tested both as a standalone treatment and in conjunction with the company's exclusive PARG inhibitor, IDE161. The target population includes patients with various solid tumor types, with B7H3/PTK7 expression observed in 30-40% of cases. Tumor types under investigation include lung, breast, ovarian, and colorectal cancer.

### Related Stocks

- [IDYA.US](https://longbridge.com/en/quote/IDYA.US.md)

## Related News & Research

- [BUZZ-IDEAYA rises after lung cancer drug combo testing deal with AstraZeneca](https://longbridge.com/en/news/282173989.md)
- [The definitive infrastructure for modern drug development](https://longbridge.com/en/news/283027097.md)
- [Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)](https://longbridge.com/en/news/282486478.md)
- [Zymeworks Sets May 7 Date to Unveil Q1 2026 Results and Pipeline Update](https://longbridge.com/en/news/283003993.md)
- [Fate Therapeutics presents preclinical AACR data on off-the-shelf CAR-T candidate FT839](https://longbridge.com/en/news/283028965.md)